Trevi Therapeutics, Inc. (TRVI) – What Are Researchers Saying About This Stock?

Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) have earned a consensus recommendation of “Moderate Buy” from the thirteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $27.08.

Several research firms have issued reports on TRVI. Weiss Ratings reiterated a “sell (d-)” rating on shares of Trevi Therapeutics in a research report on Thursday, October 15th. Raymond James Financial reissued a “strong-buy” rating and issued a $40.00 price target on shares of Trevi Therapeutics in a report on Friday, August 7th. Wall Street Zen downgraded Trevi Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Morgan Stanley restated an “overweight” rating and issued a $23.00 price target on shares of Trevi Therapeutics in a research note on Friday, August 7th. Finally, B. Riley Financial upped their price objective on Trevi Therapeutics from $21.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, July 20th.

Insider Transactions at Trevi Therapeutics

In other news, Director Michael Heffernan sold 39,473 shares of Trevi Therapeutics stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $15.09, for a total transaction of $595,647.57. Following the completion of the transaction, the director owned 6,351 shares of the company’s stock, valued at $95,836.59. The trade was a 86.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Corporate insiders own 15.39% of the company’s stock.

Hedge Funds Weigh In On Trevi Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. KBC Group NV acquired a new stake in shares of Trevi Therapeutics during the first quarter worth $29,000. Sterling Capital Management LLC increased its holdings in Trevi Therapeutics by 848.7% in the 3rd quarter. Sterling Capital Management LLC now owns 3,567 shares of the company’s stock valued at $51,000 after purchasing an additional 3,191 shares in the last quarter. Avidity Partners Management LP purchased a new stake in shares of Trevi Therapeutics during the 1st quarter valued at about $79,000. Mirae Asset Global Investments Co. Ltd. purchased a new stake in shares of Trevi Therapeutics during the third quarter valued at approximately $104,000. Finally, Amundi acquired a new position in Trevi Therapeutics in the 2nd quarter worth $192,000. 95.76% of the stock is currently owned by hedge funds and other institutional investors.

Trevi Therapeutics Stock Performance

NASDAQ TRVI opened at $14.33 on Friday. The firm’s fifty day moving average is $14.27 and its two-hundred day moving average is $14.39. Trevi Therapeutics has a one year low of $9.82 and a one year high of $20.22. The firm has a market cap of $2.04 billion, a PE ratio of -42.15 and a beta of 1.15.

Trevi Therapeutics (NASDAQ:TRVI) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.11) EPS for the quarter, hitting the consensus estimate of ($0.11). Research analysts predict that Trevi Therapeutics will post -0.48 earnings per share for the current year.

Trevi Therapeutics Company Profile

Trevi Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for chronic conditions that have limited therapeutic options. The company’s lead product candidate is Haduvio, an oral extended-release formulation of nalbuphine, an opioid receptor modulator designed to combine kappa-opioid receptor agonism with mu-opioid receptor antagonism.

Trevi is evaluating Haduvio in conditions involving chronic cough and severe itching. Its clinical development programs have included studies in chronic cough associated with idiopathic pulmonary fibrosis, a progressive lung disease, and chronic pruritus associated with systemic sclerosis, an autoimmune connective-tissue disorder.